Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
FAM114A1 influences cardiac pathological remodeling by regulating angiotensin II signaling
Kadiam C. Venkata Subbaiah, Jiangbin Wu, Wai Hong Wilson Tang, Peng Yao
Kadiam C. Venkata Subbaiah, Jiangbin Wu, Wai Hong Wilson Tang, Peng Yao
View: Text | PDF
Research Article Cardiology

FAM114A1 influences cardiac pathological remodeling by regulating angiotensin II signaling

  • Text
  • PDF
Abstract

Cardiac pathological remodeling, a primary contributor to heart failure (HF) and death, is an important target for HF therapy. However, the signaling pathways that govern cardiac remodeling are not fully elucidated. Here, we found that a functionally unannotated human myocardial infarction–associated (MI-associated) gene, family with sequence similarity 114 member A1 (FAM114A1), is induced in failing human and mouse hearts compared with nonfailing hearts. Homozygous KO of Fam114a1 (Fam114a1–/–) in the mouse genome reduces cardiomyocyte hypertrophy, inflammation, and cardiac fibrosis while restoring cardiac function in angiotensin II–induced (Ang II–induced) and MI-induced HF mouse models. Cardiac fibroblasts (CFs) exhibit the highest FAM114A1 expression among different cardiac cell types. FAM114A1 is a critical autonomous factor for CF proliferation, activation, and migration. Mechanistically, FAM114A1 interacts with angiotensin receptor–associated protein (AGTRAP) and regulates the expression of angiotensin type 1 receptor (AT1R) and downstream Ang II signaling transduction, and it subsequently influences profibrotic response. Our results indicate that FAM114A1 regulates Ang II signaling, thereby activating CFs and other cardiac cells and augmenting pathological cardiac remodeling. These findings provide potentially novel insights into the regulation of cardiac remodeling and identify FAM114A1 as a therapeutic target for the treatment of heart disease.

Authors

Kadiam C. Venkata Subbaiah, Jiangbin Wu, Wai Hong Wilson Tang, Peng Yao

×

Figure 6

FAM114A1 depletion stabilizes AGTRAP, enhances AT1R degradation, and influences Ang II signaling in cardiac fibroblasts.

Options: View larger image (or click on image) Download as PowerPoint
FAM114A1 depletion stabilizes AGTRAP, enhances AT1R degradation, and inf...
(A) Immunoprecipitation and immunoblot confirm the interaction of FAM114A1 with AGTRAP in the mouse heart tissue lysates. This experiment was repeated 3 times, and representative images are shown. (B) IF detection of overexpressed EGFP-tagged FAM114A1 and Myc-tagged AGTRAP in mouse NIH/3T3 fibroblast cells. Protein expression changes were observed after 3 hours and 24 hours after Ang II or vehicle treatment. Scale bar: 50 μm. This experiment was repeated 3 times, and representative images are shown. (C) Western blot measurement and quantification of FAM114A1, AGTRAP, and AT1R in vehicle or Ang II–treated primary CF cells isolated from WT and Fam114a1–/– mice. Separate gels were run for detecting FAM114A1 and AGTRAP compared with AT1R and GAPDH. (D) Western blot measurement and quantification of p-ERK1/2, ERK1/2, p-AKT, AKT, p-p38, and p38 in Ang II– or vehicle-treated CFs (24 hours) from hearts of WT and Fam114a1–/– mice (n = 3). (E) Representative images of IF staining and quantification of normalized intensity of MF activation markers in CFs of WT and Fam114a1–/– mice with control or Agtrap siRNA transfection followed by vehicle or Ang II (1 μM) treatment. n = 100 cells were analyzed for each group. Scale bar: 30 μm. Data are presented as mean ± SEM. Statistical significance was confirmed by 2-way ANOVA with Tukey’s multiple-comparison test for C–E. *P < 0.05; **P < 0.01; ***P <0.001;.****P <0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts